Search Results

Radioligands have been used to study GPCRs for decades, but with the advances in the fluorescence field, assays They are ligands labeled with radioactive isotopes which can be used in binding assays to quantify other that offer an alternative to radioligands in binding assays. design for specific targets:  Not all targets have available high-affinity radioligands, but with the development GPCR-radioligand binding assays.

Overcoming them requires careful assay design and strategic use of the right fluorescent probes. For GPCR assay developers, HCS supports:  Quantitative visualization of receptor internalization and trafficking  • Live-cell kinetic measurements  unavailable to endpoint assays  Multiplexed assessment the gold standard for image-based GPCR assays. development expertise.

Imagine running a calcium assay and discovering your compound shows only weak activity. Kenakin dives deep into a widely used, often misunderstood tool in early drug discovery: the calcium assay Revered for its convenience, the FLIPR assay provides rapid insights into receptor activity. with strategic clarity. 📍 Foundational Level | Calcium Assays 📚 Part of Terry Kenakin’s Pharmacology Unlock "Calcium Assays" now

Many pharmacology experiments produce beautifully clean assay curves. The harder question is what those assay signals actually predict biologically. Drug discovery programs rarely fail because an assay produced poor data. The Assay Window Problem Every functional assay operates within a measurement window , and interpreting The Corner is built for: pharmacologists refining core analytical tools discovery teams navigating development

Enhance your GPCR research with deeper assay insights for more effective results. Terry's Corner – Assay Volume Control in GPCR Drug Discovery This week in Terry’s Corner, you’ll learn But behind every “new” assay is a decade of design, failure, and rethinking.

Thus we propose the use of fluorescent probes in GPCR screening assays due to their numerous advantages The advantages of Fluorescent Probes in GPCR assays over other methods Fluorescent ligands are made by The traditional binding assays for GPCRs use radioligands, whose limitations, especially safety concerns At Celtarys, we focus on developing fluorescent tools that keep minimal background signal even without common starting point for employing fluorescent probes in GPCR assays.

The strategic challenge is knowing which early assays are truly non-negotiable, which mechanisms demand In this session, you’ll gain: Clarity on high-impact early safety assays and their compelling rationale Kenakin highlights the definitive role of patch clamp assays and how high-throughput adaptations have Liver-centric assays identify primary and secondary toxic mechanisms Reactive metabolite detection is generate such species are deprioritized or redesigned before entering expensive development stages.

New scaffolds modulating the CBRs in both the orthosteric and allosteric sites have been developed, supported by resolved crystal structures of both CBRs.[4–8] A key challenge in CBR modulator development is separating Results 2.1  CELT-335 Binding at CB1 and CB2 Receptors The first step for the development of the assay Using these results as a starting point, the Tag-lite® binding assay was developed. and the Tag-lite® binding assay developed in this work. ( a ) CB1R binding affinities; ( b ) CB2R binding

Assay volume control does just that. It’s about revealing therapeutic liabilities before  they derail development. The real question: are you letting your assay system dictate the wrong story? between a high-affinity/low-efficacy agonist  versus a high-efficacy agonist  before entering costly development Clarify whether observed effects reflect true pharmacology or assay artifacts .

August 2022 In vitro assays for the functional characterization of (psychedelic) substances at the serotonin More specifically, this review covers assays to monitor the canonical G protein signaling pathway (e.g measuring G protein recruitment/activation, inositol phosphate accumulation, or Ca2+ mobilization), assays recruitment or signaling, and assays to monitor receptor conformational changes. mechanism and linked to its specific execution, as these may heavily impact the assay outcome."

physiological processes, making them a key target in drug development.   This technology enhances sensitivity and assay specificity . In a recent study , we contributed to the development of a robust HTRF assay for the discovery of new Saturation assays using CELT-335. By combining deep expertise in GPCR biology with advanced fluorescence chemistry, Celtarys custom-developed

The dysfunction of these receptors has been linked to the development of many serious pathologies, like Thus, developing assays for commercially available probes such as CELT-419 would facilitate research Probe characterization and assay development and validation 3.1  Characterization of CELT-419 in radioligand To validate that the developed assay is suitable for measuring the K i of different ligands, competition Altogether, the development of similar probes for other GPCRs and further development of measurement

Every GPCR assay that makes it to market carries years of failures, late-night ideas, risky bets, and Functional assays for GPCRs—especially Gq-coupled receptors—were notoriously messy. Calcium flux? Built to Fail, Built to Win: The IP One Gamble After the success of their cAMP assay, Trinquet’s team took a risky bet: develop a functional readout for Gq signaling without relying on calcium. Months were spent debating assay design. IP1 isn’t naturally abundant or easy to detect.

Industry insights:  New alliances, pipeline shifts, and platform tech that could reshape metabolic drug development Localization Matters : Protein complexes pre-assemble at membranes, altering how ligands trigger responses. • Assay Development Gets Real : Fluorescent tools and real-world biology don’t always match. University access are coming—grandfather pricing ends in 2026. • Inclusive Growth : More access for developing Whether you’re designing the next assay, scouting a new therapeutic angle, or exploring career pivots

Here we developed and validated a label-free, liquid chromatography-mass spectrometry (LC-MS) based cell binding assay, using centrifugation to separate binders from non-binders. This assay was applied to various target classes, with particular emphasis on those for which protein-based binding assay can be difficult to achieve. binding affinity was consistent with functional assays.

partnership with Eurofins DiscoverX , a global leader in GPCR product solutions including cell-based assay product solutions supporting drug discovery, development, and regulatory submission. enable rigorous pharmacological characterization and confident decision-making across the discovery and development technologies across discovery and development.” providing industry-standard, regulatory-accepted platforms spanning basic research, drug discovery, and development

Too often, fundamentals are undervalued: in vitro assays are treated as routine checkboxes, and ADME Predictive in vitro assays have dramatically reduced this attrition—but with success comes complacency Kenakin highlights predictive in vitro permeation assays  that enable early iteration Absorption failures Predictive Assays: Assumptions and Opportunities High-throughput PK panels have transformed discovery vitro–in vivo correlation depends on scaling assumptions and controls CYP inhibition, transporter assays

“We don’t just deliver compounds, we solve assay problems.” — Dr. Maria Majellaro Celtarys specializes in the custom development of fluorescent ligands  using a modular Democratize access to high-performance chemical probes and make assay development faster, cheaper, and workflow on the company page . _______________ Keyword Cloud:   GPCR data platform , fluorescent ligands , assay development , GPCR research community , Dr.

Eric Trinquet Built to Fail, Built to Win: Inside the IP1 Assay Origin Story The IP-One assay didn’t Originally developed as ultra-bright lanthanide probes, the team realized they could tune these molecules Mini Timeline 🎯 Early 2000s: Trinquet leads IP1 & Tag-lite development 🧪 Mid-2010s: Rare-earth scaffold “We did a full dose-response and saw antagonism—all in one plate-based assay. Product development isn’t just about science.

offset rates (not just “final numbers”) decide which drugs succeed in patients and which ones die in development kinetics ✅ A framework to classify antagonists and rank compounds by offset rate, using rapid calcium assays The Hemi-Equilibrium Problem Calcium assays look simple. Flip it around, and you’ve got a shortcut: use depression of max in calcium assays to rapidly rank offset The reality is dynamic—ligands arrive, depart, and interact in ways that standard assays often miss.

Does Your Assay Agree With the Literature? Your experiment gives a pKB of 8.0. Is that consistent, or is your assay biased? to: Confirm whether your mean truly overlaps with accepted values Verify if binding and functional assays interchangeable with existing ones Instead of vague comparisons, you’ll have statistical clarity on whether your assay suggestions Practical insights  distilled from decades of pharmacology experience Whether you’re validating assays

Understanding the molecular binding mechanism behind C5a and C5aR interaction is crucial for developing To accelerate ligand development for C5aR, new tools must be developed . This method has been validated for developing fluorescent ligands with optimal properties for different Development process of fluorescent probes using Celtarys technology and its stages. C5aR Fluorescent Ligand Development Initially, a detailed analysis of the published ligands for C5aR

A compound shows no response in one assay, and we call it “selective.” It should hold regardless of receptor density or assay format. A development decision may hinge on assay sensitivity rather than molecular behavior. Modern assays allow isolation of discrete signaling nodes. It prevents false negatives caused by insensitive assays.

August 2022 Luciferase-based GloSensor™ cAMP assay: Temperature optimization and application to cell-based The GloSensor™ cAMP assay enables real-time monitoring of signaling downstream of many GPCRs. However, it is crucial to optimize assay conditions such as temperature. Here, we describe the temperature sensitivity and reversibility of the GloSensor™ cAMP assay, and which Nevertheless, the GloSensor™ cAMP assay can be applied to analyze signaling by a wide range of GPCRs

2026 GPCR Pharmacology AMA: Receptor Theory, Biased Signaling & Assay Interpretation The first GPCR Pharmacology Kenakin will address receptor theory, assay interpretation, biased signaling, and practical drug discovery coefficients (log(τ/KA) or log(max/EC50)) Systematic comparison of biased agonists using modern functional assays For scientists working in GPCR programs, this connects functional assay data directly to translational What seems definitive during early screening can shift as assay systems, receptor expression levels,

Watch Episode 176 The first time Michelle ran a cyclic AMP assay, she did it with a single-channel pipette Assay samples were layered on trays of ice. These weren’t quaint inconveniences. We were doing assays on ice, pipetting one sample at a time. Those early cyclic AMP assays weren’t just cold and slow — they were part of a bigger puzzle. Mini Timeline: Manual assay years — technical rigor as foundation Technology boom — scaling curiosity

When Sokhom joined Alkermes, the company had a strong development arm, but a relatively underdeveloped tasked with building an in vitro pharmacology group from scratch , including infrastructure, hiring, assay development, and team dynamics.

affinity experiments  are interpreted—and how those interpretations quietly shape SAR, lead selection, and development By walking through saturation curves, displacement assays, stoichiometry pitfalls, and kinetic traps, experiments that tell the truth , ensuring affinity data support—rather than undermine—lead selection and development Research , leaders from academia and biotech unpack what effective collaboration really looks like when developing event alerts, and career-relevant opportunities—organized to support real decisions in discovery and development

cancers, particularly in combination with other immune checkpoint inhibitors.1 In a shared effort to develop A new NanoBRET® competitive binding assay 2  was developed in collaboration with Professor Kevin Pfleger Pfleger’s group in developing assays, led to two new A 2A AR tracers (CELT-463 and CELT-464) , bearing First, saturation binding assays were performed . E. 1-Alkyl-8-(Piperazine-1-Sulfonyl)Phenylxanthines: Development and Characterization of Adenosine A2B

Functional assays can suggest clarity while quietly masking complexity, creating the illusion of competitive Each experimental decision — system sensitivity, assay configuration, kinetic design — carries strategic Assay Sensitivity and System Configuration Receptor expression level is a strategic variable. Best Habits for Data Quality and Reproducibility Detection assays identify activity; they do not validate promising hits into mechanistic evaluation quickly Use statistics to arbitrate interpretation Design assays